-
Ab179444-10μlApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.
-
Ab179444-1mlApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.
-
Ab179444-20μlApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.
-
Ab179444-50μlApplicationWB: 1/2,000-1/10,000 : Predicted molecular weight: 54 kDaFlow: 0.008 μg/mL – 1 μg/mLICC/IF: 2 μg/mL.
-
Ab177923-100μgVofatamab (anti-FGFR3) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab (anti-FGFR3) blocks activation of both the wildtype and genetically activated receptor. Vofatamab (anti-FGFR3) can be used in the research of metastatic urothelial
-
Ab177923-10mgVofatamab (anti-FGFR3) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab (anti-FGFR3) blocks activation of both the wildtype and genetically activated receptor. Vofatamab (anti-FGFR3) can be used in the research of metastatic urothelial
-
Ab177923-1mgVofatamab (anti-FGFR3) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab (anti-FGFR3) blocks activation of both the wildtype and genetically activated receptor. Vofatamab (anti-FGFR3) can be used in the research of metastatic urothelial
-
Ab177923-5mgVofatamab (anti-FGFR3) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab (anti-FGFR3) blocks activation of both the wildtype and genetically activated receptor. Vofatamab (anti-FGFR3) can be used in the research of metastatic urothelial
-
Ab177921-100μgVolagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).
-
Ab177921-10mgVolagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).
-
Ab177921-1mgVolagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).
-
Ab177921-5mgVolagidemab (anti-GCGR) is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab (anti-GCGR) can be used in the research of type 1 diabetes (T1D).